跳至主要内容
临床试验/KCT0006930
KCT0006930招募中未知

Pragmatic clinical trial of initiating urate lowering therapy during acute gout attack

Seoul Metropolitan Government Seoul National University Boramae Medical Center0 个研究点目标入组 305 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
305

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 o Limit(—)
性别
All

入选标准

  • 1) Korean adult men and women aged 19 or older
  • 2) At screening, patients diagnosed with acute gout according to 1977 American College of Rheumatology classification criteria for acute gout
  • 3) Patients who need to start urate lowering therapy. The indications for urate lowering therapy as follows.
  • ? have one or more tophis
  • ? have acute gout flare more than once a year
  • ? Gout arthritis on X-rays of the hands or feet
  • ? when the physicians determines that urate lowering therapy is necessary
  • 4) Patients who provided written informed consent for the clinical trial

排除标准

  • 1) Patients with ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease, severe congestive heart failure patients and congestive heart failure patients (NYHA II~IV), uncontrolled hypertensive patients (SBP 180 mmHg or DBP 110 mmHg and above)
  • 2) Patients with a history of gastrointestinal bleeding or perforation related to previous NSAID therapy, active peptic ulceration or bleeding
  • 3) Patients with a history of cerebral hemorrhage or systemic bleeding, or with coagulation disorders or severe hematologic disorders
  • 4) Individuals with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • 5) Patients with inflammatory bowel diseases such as Crohn's disease or ulcerative colitis
  • 6) Patients with a history of hypersensitivity reactions or clinically significant hypersensitivity reactions to urate-lowering therapies, such as colchicine, which are investigational drugs
  • 7) Patients with a history of hypersensitivity reactions, asthma, rhinitis, nasal polyps, urticaria, allergic reactions to aspirin or other NSAIDs, or a history thereof
  • 8) Pregnant or breastfeeding women, defined as women from the time of conception to the end of pregnancy, with a positive urine pregnancy test result. Also, those who do not consent to the use of appropriate contraceptive methods during the clinical trial period
  • 9) For fertile women, those who do not agree to adhere to medically acceptable contraceptive methods for a minimum of 7 days during the clinical trial period and after the end of the trial
  • 10) A patient who has received corticosteroids or urate-lowering medications (allopurinol, febuxostat, benzbromarone) within 4 weeks prior to screening
  • 11) Individuals who have received or plan to receive mercaptopurine or azathioprine within 1 week or a period longer than 5 times the half-life from the screening
  • 12) Patients with severe renal impairment (eGFR <50mL/min/1.73 m2)
  • 13) Patients with severe hepatic impairment (AST, ALT, or total bilirubin levels greater than 3 times the upper limit of normal)
  • 14) Patients who have participated in other clinical trial and have been exposed to investigational drugs or investigational medical devices within 4 weeks prior to screening
  • 15) Individuals with a history of alcohol addiction or substance abuse within the past 5 years from the screening date
  • 16) Individuals with clinically significant diseases, as determined by the investigator, that would warrant exclusion from this study

研究者

发起方
Seoul Metropolitan Government Seoul National University Boramae Medical Center

相似试验